FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897350221> ?p ?o ?g. }

• W2897350221 abstract "The evolution of radiotherapy over recent decades has reintroduced the hypofractionation for many tumor sites with similar outcomes to those of conventional fractionated radiotherapy. The use of hypofractionation in locally advanced head and neck cancer (LAHNC) has been already used, however, its use has been restricted to only a few countries. The aim of this trial was to evaluate the safety and feasibility of moderate hypofractionated radiotherapy (HYP-RT) with concomitant cisplatin (CDDP).This single-arm trial was designed to evaluate the safety and feasibility of HYP-RT with concomitant CDDP in LAHNC. Stage III and IV patients withnonmetastatic disease were enrolled. Patients were submitted to intensity modulatedradiation therapy, which comprised 55 Gy/20 fractions to the gross tumor and44-48 Gy/20 fractions to the areas of subclinical disease. Concomitant CDDPconsisted of 4 weekly cycles of 35 mg/m2. The primary endpoints were the treatment completion rate and acute toxicity.Twenty patients were enrolled from January 2015 to September 2016, and 12 (60%) were classified as unresectable. All patients completed the total dose of radiotherapy, and 19 patients (95%) received at least 3 of 4 cycles of chemotherapy. The median overall treatment time was 29 days (27-34). Grade 4 toxicity was reported twice (1 fatigue and 1 lymphopenia). The rates of grade 3 dermatitis and mucositis were 30% and 40%, respectively, with spontaneous resolution. Nasogastric tubes were offered to 15 patients (75%) during treatment; 4 patients (20%) needed feeding tubes after 2 months, and only 1 patient needed a feeding tube after 12 months.HYP-RT with concomitant CDDP was considered feasible for LAHNC, and the rate of acute toxicity was comparable to that of standard concomitant chemoradiation. A feeding tube was necessary for most patients during treatment. Further investigation of this strategy is warranted.ClinicalTrials, NCT03194061 . Registered 21 Jun 2017 - Retrospectively registered." @default.
• W2897350221 created "2018-10-26" @default.
• W2897350221 creator A5006119098 @default.
• W2897350221 creator A5010937182 @default.
• W2897350221 creator A5011385272 @default.
• W2897350221 creator A5015167643 @default.
• W2897350221 creator A5022269577 @default.
• W2897350221 creator A5023703060 @default.
• W2897350221 creator A5039784419 @default.
• W2897350221 creator A5048348109 @default.
• W2897350221 creator A5053268860 @default.
• W2897350221 creator A5055516546 @default.
• W2897350221 creator A5060474811 @default.
• W2897350221 creator A5071694790 @default.
• W2897350221 creator A5072408750 @default.
• W2897350221 creator A5074481826 @default.
• W2897350221 creator A5077673587 @default.
• W2897350221 creator A5079940663 @default.
• W2897350221 date "2018-10-23" @default.
• W2897350221 modified "2023-10-02" @default.
• W2897350221 title "Feasibility of concomitant cisplatin with hypofractionated radiotherapy for locally advanced head and neck squamous cell carcinoma" @default.
• W2897350221 cites W1567253907 @default.
• W2897350221 cites W1830334259 @default.
• W2897350221 cites W1993359381 @default.
• W2897350221 cites W2011079780 @default.
• W2897350221 cites W2020378886 @default.
• W2897350221 cites W2029042167 @default.
• W2897350221 cites W203234415 @default.
• W2897350221 cites W2036005555 @default.
• W2897350221 cites W2062253457 @default.
• W2897350221 cites W2063687155 @default.
• W2897350221 cites W2069452545 @default.
• W2897350221 cites W2081124009 @default.
• W2897350221 cites W2085052317 @default.
• W2897350221 cites W2086622372 @default.
• W2897350221 cites W2089257078 @default.
• W2897350221 cites W2100961085 @default.
• W2897350221 cites W2105779974 @default.
• W2897350221 cites W2110569576 @default.
• W2897350221 cites W2110664940 @default.
• W2897350221 cites W2119184505 @default.
• W2897350221 cites W2120046399 @default.
• W2897350221 cites W2132801136 @default.
• W2897350221 cites W2146488048 @default.
• W2897350221 cites W2148754315 @default.
• W2897350221 cites W2171524637 @default.
• W2897350221 cites W2313665888 @default.
• W2897350221 cites W2546486432 @default.
• W2897350221 cites W2559848388 @default.
• W2897350221 cites W2586403573 @default.
• W2897350221 cites W2597041194 @default.
• W2897350221 cites W2740402187 @default.
• W2897350221 cites W3021410191 @default.
• W2897350221 cites W4243024322 @default.
• W2897350221 doi "https://doi.org/10.1186/s12885-018-4893-5" @default.
• W2897350221 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6199702" @default.
• W2897350221 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30352576" @default.
• W2897350221 hasPublicationYear "2018" @default.
• W2897350221 type Work @default.
• W2897350221 sameAs 2897350221 @default.
• W2897350221 citedByCount "21" @default.
• W2897350221 countsByYear W28973502212020 @default.
• W2897350221 countsByYear W28973502212021 @default.
• W2897350221 countsByYear W28973502212022 @default.
• W2897350221 countsByYear W28973502212023 @default.
• W2897350221 crossrefType "journal-article" @default.
• W2897350221 hasAuthorship W2897350221A5006119098 @default.
• W2897350221 hasAuthorship W2897350221A5010937182 @default.
• W2897350221 hasAuthorship W2897350221A5011385272 @default.
• W2897350221 hasAuthorship W2897350221A5015167643 @default.
• W2897350221 hasAuthorship W2897350221A5022269577 @default.
• W2897350221 hasAuthorship W2897350221A5023703060 @default.
• W2897350221 hasAuthorship W2897350221A5039784419 @default.
• W2897350221 hasAuthorship W2897350221A5048348109 @default.
• W2897350221 hasAuthorship W2897350221A5053268860 @default.
• W2897350221 hasAuthorship W2897350221A5055516546 @default.
• W2897350221 hasAuthorship W2897350221A5060474811 @default.
• W2897350221 hasAuthorship W2897350221A5071694790 @default.
• W2897350221 hasAuthorship W2897350221A5072408750 @default.
• W2897350221 hasAuthorship W2897350221A5074481826 @default.
• W2897350221 hasAuthorship W2897350221A5077673587 @default.
• W2897350221 hasAuthorship W2897350221A5079940663 @default.
• W2897350221 hasBestOaLocation W28973502211 @default.
• W2897350221 hasConcept C116263406 @default.
• W2897350221 hasConcept C126322002 @default.
• W2897350221 hasConcept C141071460 @default.
• W2897350221 hasConcept C143998085 @default.
• W2897350221 hasConcept C155806632 @default.
• W2897350221 hasConcept C2776530083 @default.
• W2897350221 hasConcept C2776833033 @default.
• W2897350221 hasConcept C2778045676 @default.
• W2897350221 hasConcept C2778496288 @default.
• W2897350221 hasConcept C2779384505 @default.
• W2897350221 hasConcept C2780140570 @default.
• W2897350221 hasConcept C29730261 @default.
• W2897350221 hasConcept C509974204 @default.
• W2897350221 hasConcept C71924100 @default.
• W2897350221 hasConceptScore W2897350221C116263406 @default.
• W2897350221 hasConceptScore W2897350221C126322002 @default.
• W2897350221 hasConceptScore W2897350221C141071460 @default.

• next